LOTTE Biologics Strengthens North America Footprint, Accelerates Global CDMO Order Momentum

LOTTE Biologics is accelerating the expansion of its contract development and manufacturing organization (CDMO) business, centered on its Syracuse Bio Campus in New York, as it prepares for the launch of its first production plant at the Incheon Songdo Bio Campus next year.

This strategy is designed to establish a strong track record early in the United States—the world’s largest pharmaceutical and biotechnology market and one of the most stringent regulatory environments. By securing experience and credibility in the U.S. market in advance, LOTTE Biologics aims to support the early stabilization of its Songdo facility, which will serve as a hub for large-scale commercial manufacturing, while also driving rapid growth in future CDMO orders.

According to industry sources on the 27th, LOTTE Biologics has officially disclosed a total of four CDMO contracts secured at its Syracuse campus—three in the previous year and one this year...

Read the full article:

북미 기반 다진 롯데바이오로직스…글로벌 CDMO 수주 속도 높인다 | 서울경제